$7.44
0[0.00%]
Last update: 4:00PM Get Real Time Here
Cogent Biosciences
(NASDAQ:COGT)Cogent Biosciences Stock (NASDAQ:COGT), Analyst Ratings, Price Targets, Predictions
Cogent Biosciences Inc has a consensus price target of $18.36, established from looking at the 36 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Needham, and JP Morgan on May 13, 2024, May 8, 2024, and February 27, 2024. With an average price target of $19 between HC Wainwright & Co., Needham, and JP Morgan, there's an implied 155.38% upside for Cogent Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Needham
JP Morgan
Citigroup
Baird
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cogent Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2024 | Buy Now | 155.38% | HC Wainwright & Co. | Robert Burns | → $19 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 141.94% | Needham | Ami Fadia | → $18 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2024 | Buy Now | 168.82% | JP Morgan | Anupam Rama | $18 → $20 | Maintains | Overweight | Get Alert |
| 02/26/2024 | Buy Now | 74.73% | Citigroup | David Lebowitz | $11 → $13 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | 7.53% | Baird | Joel Beatty | $14 → $8 | Downgrade | Outperform → Neutral | Get Alert |
| 02/26/2024 | Buy Now | 141.94% | Needham | Ami Fadia | → $18 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 34.41% | Wedbush | David Nierengarten | $5 → $10 | Maintains | Neutral | Get Alert |
| 02/12/2024 | Buy Now | 101.61% | Needham | Ami Fadia | → $15 | Reiterates | Buy → Buy | Get Alert |
| 02/08/2024 | Buy Now | 47.85% | Citigroup | David Lebowitz | → $11 | Initiates | → Buy | Get Alert |
| 12/15/2023 | Buy Now | 74.73% | HC Wainwright & Co. | Robert Burns | $27 → $13 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | -32.8% | Wedbush | David Nierengarten | $20 → $5 | Downgrade | Outperform → Neutral | Get Alert |
| 12/08/2023 | Buy Now | 141.94% | JP Morgan | Anupam Rama | → $18 | Initiates | → Overweight | Get Alert |
| 12/05/2023 | Buy Now | 195.7% | Needham | Ami Fadia | → $22 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2023 | Buy Now | 195.7% | Needham | Ami Fadia | → $22 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2023 | Buy Now | 195.7% | Needham | Ami Fadia | → $22 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 195.7% | Needham | Ami Fadia | → $22 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2023 | Buy Now | 262.9% | HC Wainwright & Co. | Robert Burns | → $27 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 195.7% | Needham | Ami Fadia | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/13/2023 | Buy Now | 249.46% | Guggenheim | Charles Zhu | → $26 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | 195.7% | Piper Sandler | Christopher Raymond | → $22 | Maintains | Overweight | Get Alert |
| 06/08/2023 | Buy Now | 262.9% | HC Wainwright & Co. | Robert Burns | $28 → $27 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | 182.26% | Needham | Ami Fadia | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 182.26% | Needham | Ami Fadia | → $21 | Reiterates | Buy → Buy | Get Alert |
| 04/28/2023 | Buy Now | 168.82% | Baird | Joel Beatty | → $20 | Initiates | → Outperform | Get Alert |
| 04/19/2023 | Buy Now | 209.14% | Needham | Ami Fadia | → $23 | Maintains | Buy | Get Alert |
| 03/27/2023 | Buy Now | 276.34% | HC Wainwright & Co. | Robert Burns | → $28 | Assumes | → Buy | Get Alert |
| 03/15/2023 | Buy Now | 249.46% | Guggenheim | Charles Zhu | → $26 | Reiterates | → Buy | Get Alert |
| 03/15/2023 | Buy Now | 209.14% | Needham | Ami Fadia | $24 → $23 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 168.82% | SVB Leerink | Andrew Berens | $18 → $20 | Maintains | Outperform | Get Alert |
| 12/14/2022 | Buy Now | 222.58% | Needham | Ami Fadia | → $24 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Cogent Biosciences (COGT)?
The latest price target for Cogent Biosciences (NASDAQ: COGT) was reported by HC Wainwright & Co. on May 13, 2024. The analyst firm set a price target for $19.00 expecting COGT to rise to within 12 months (a possible 155.38% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cogent Biosciences (COGT)?
The latest analyst rating for Cogent Biosciences (NASDAQ: COGT) was provided by HC Wainwright & Co., and Cogent Biosciences reiterated their buy rating.
When was the last upgrade for Cogent Biosciences (COGT)?
There is no last upgrade for Cogent Biosciences.
When was the last downgrade for Cogent Biosciences (COGT)?
The last downgrade for Cogent Biosciences Inc happened on February 26, 2024 when Baird changed their price target from $14 to $8 for Cogent Biosciences Inc.
When is the next analyst rating going to be posted or updated for Cogent Biosciences (COGT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cogent Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cogent Biosciences was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
Is the Analyst Rating Cogent Biosciences (COGT) correct?
While ratings are subjective and will change, the latest Cogent Biosciences (COGT) rating was a reiterated with a price target of $0.00 to $19.00. The current price Cogent Biosciences (COGT) is trading at is $7.44, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.